Vigonvita Life Sciences

2630 · HKEX

Public Market Listing

2630HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Vigonvita Life Sciences are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
Serotonin transporter + 5-HT3 receptorSmall molecule
Major Depressive Disorder
Phase 2
Dopamine and serotonin receptors (multi-target antipsychotic)Small molecule
Schizophrenia

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
September 2027 (1)
LV232Phase 2MDD
Est. primary completion 2027-09-01 · NCT06828887 · CT.gov ↗
What to watch
October 2027 (1)
VV119Phase 2Schizophrenia
Est. primary completion 2027-10-31 · NCT07703956 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q4————report ↗